Keeping the flame alive

Two companies, Genomics Collaborative and Graffinity, have done deals with big pharma and big biotech, respectively, which they said keep them on course as alternatives to the pure product development business model.

While most discovery companies refocused on products after the genomics bubble burst in 2000, Genomics Collaborative Inc. made a conscious decision to stick with its service business. The company now says it is six to nine months away from being cash flow positive, having signed 90-100 revenue-generating agreements over the past two-and-a-half years with about 35 companies...